Drugmakers partnered with the U.S. government are on track to begin actively manufacturing a vaccine for COVID-19 by the end of the summer, a senior administration official said.

Pfizer Inc. and partner BioNTech SE said two of their experimental coronavirus vaccines received ‘fast track’ designation from the U.S. health agency, speeding up the regulatory review process.

Boston-based Dewpoint Therapeutics and Merck will collaborate to develop a novel mechanism for the treatment of HIV by harnessing Dewpoint’s proprietary platform for condensate-based drug discovery.

Ovid Therapeutics and Angelini Pharma entered into an exclusive license agreement to develop, manufacture and commercialize OV101 for the treatment of Angelman syndrome in Europe.

21GRAMS, a breakout healthcare firm and one of W2O’s operating firms, is doubling down on creativity with the appointment of Tom Richards as Co-Global Chief Creative Officer.

Blackstone Life Sciences V fund closed at its hard cap of $4.6 billion of total capital commitments, marking the largest life sciences private fund that raised to date.

BioNTech and Pfizer’s Covid-19 vaccine candidate is expected to be ready to seek regulatory approval by the end of 2020, the Wall Street Journal reported, citing the German biotech firm’s chief executive officer.

Kymera Therapeutics entered a strategic collaboration deal with Sanofi focused on developing and commercializing protein degrader therapies that target IRAK4 in immune-inflammatory diseases, such as rheumatoid arthritis.

Harbour BioMed closed a $102 million Series C funding round that will be used to advance the company’s oncology and immunology portfolio.

With $30 million in Series A funding, Tranquis Therapeutics launches with a mission of revolutionizing the management of neurodegenerative and aging-related diseases through the advancement of a novel immuno-neurology treatment approach.